PharmaCyte Biotech, Inc.
PMCBHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. With a market capitalization of $3.8M, it sits in micro-cap territory. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Market Cap
$3.8M
Beta
0.68
P/E (TTM)
—
P/E (Fwd)
-0.93
EPS (TTM)
$-2.31
EPS (Fwd)
$-0.38
ROE
-44.0%
ROA
-8.3%
Cash
$30.5M
Total Debt
$0
Free CF
$2.6M
52W Change
-64.0%
Annual Financials
Cash vs Debt
Where PMCB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PMCB finished 46.03% below its 150-day moving average ($0.63) and 49.25% below its 200-day moving average ($0.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PMCB overbought or oversold?
At the October 20, 2026 close, PMCB's RSI(14) was 28.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
PharmaCyte Biotech, Inc. reports $30.5M in cash and $0 in total debt. Annual free cash flow of $2.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -44.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
PMCB's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence PharmaCyte Biotech, Inc.'s trajectory.